Verified employee & interview reviews

Marksans Pharma Reviews

Mumbai, Maharashtra

—/ 5

0 reviews

Marksans Pharma Limited is a prominent Indian pharmaceutical company with an extensive global footprint, primarily specializing in the research, manufacturing, and marketing of finished dosage pharmaceutical formulations. Established originally in 1992 and incorporated as a public limited entity, the company has grown into a major international player, heavily focused on generic formulations within both the Over-the-Counter (OTC) and prescription (Rx) markets. Headquartered in Mumbai, Maharashtra, the organization is publicly traded on major Indian stock exchanges, including the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) under the ticker MARKSANS. The core business model of Marksans Pharma integrates robust research and development capabilities with large-scale international commercialization. The company manages a highly diversified product portfolio comprising over 300 registered products and more than 1,500 Stock Keeping Units (SKUs). These offerings cross into multiple vital therapeutic categories, including significant segments in pain management, upper respiratory treatments, digestive health, vitamins, minerals, and supplements (VMS), and skincare. On the prescription side, Marksans provides critical therapies for cardiovascular systems, central nervous systems, oncology, anti-diabetics, and antibiotics. Operationally, Marksans operates a sophisticated infrastructure comprising four manufacturing plants and four specialized R&D centers globally. Domestically, its primary manufacturing presence is located in Goa, which houses an expansive facility with a scalable capacity of billions of units per annum, alongside a plant acquired from Teva to enhance high-volume generic production. Internationally, the company operates manufacturing facilities and R&D infrastructure strategically located in the United Kingdom and the United States. Its production units maintain strict compliance and have garnered prestigious regulatory accreditations from international bodies, including the USFDA, UK MHRA, Australian TGA, European Medicines Agency (EMA), and Health Canada. With an active global commercial presence across more than 50 countries, Marksans Pharma drives the vast majority of its revenue from highly regulated markets. The United States and the United Kingdom serve as its key commercial hubs, together accounting for a substantial majority of its operational turnover. Notably, the company is ranked among the top five Indian pharmaceutical companies operating within the United Kingdom. It also maintains growing market shares through dedicated subsidiaries in Germany, Australia, New Zealand, Brazil, the Philippines, Russia, and Canada. Financially, Marksans Pharma demonstrates robust health and consistent growth, supported by a workforce of over 2,000 employees worldwide. Under the leadership of Founder, Promoter, and Managing Director Mark Saldanha alongside CFO Jitendra Sharma, the company reports strong operating revenues and high profitability margins, while maintaining a comfortable, net debt-free solvency position with significant cash balances to secure future strategic expansions. Consistent with modern corporate expectations, Marksans actively integrates Environmental, Social, and Governance (ESG) frameworks to encourage sustainable waste management, reduce emission footprints, and sponsor preventive healthcare and community welfare projects across its active operational regions.